Vu Truong Biography and Net Worth

He has more than 20 years of experience in biopharmaceutical drug development, having held positions of increasing responsibilities in companies which were eventually acquired by larger entities, including Gene Medicine (sold to Megabios), Aviron (sold to MedImmune) and MedImmune (sold to Astra Zeneca). Having maintained a life-long interest in infectious diseases, he has focused on researching and developing innovative human monoclonal antibodies and vaccines designed to address life-threatening infections. His product development experience includes FluMist™, Synagis™ mAb and a number of other monoclonal antibody-based therapeutics. Dr. Truong is the principal architect of Aridis’ technologies, which includes a range of anti-infective products and pharmaceutical processing technologies. He received his Ph.D. in Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.

How old is Vu Truong?: Dr. Truong is currently 60 years old. There are 4 older executives and no younger executives at Aridis Pharmaceuticals. The oldest executive at Aridis Pharmaceuticals is Dr. Eric J. Patzer Ph.D., Founder & Executive Chairman, who is 75 years old. Learn More on Vu Truong's age.
How do I contact Vu Truong?: The corporate mailing address for Dr. Truong and other Aridis Pharmaceuticals executives is 5941 Optical Ct, San Jose CA, 95138. Aridis Pharmaceuticals can also be reached via phone at (408) 385-1742 and via email at [email protected]. Learn More on Vu Truong's contact information.
Has Vu Truong been buying or selling shares of Aridis Pharmaceuticals?: Vu Truong has not been actively trading shares of Aridis Pharmaceuticals in the last ninety days. Most recently, on Tuesday, July 27th, Vu Truong bought 5,000 shares of Aridis Pharmaceuticals stock. The stock was acquired at an average cost of $5.11 per share, with a total value of $25,550.00. Learn More on Vu Truong's trading history.
Who are Aridis Pharmaceuticals' active insiders?: Aridis Pharmaceuticals' insider roster includes John Hamilton (Director), and Vu Truong (CEO). Learn More on Aridis Pharmaceuticals' active insiders.

Vu Truong Insider Trading History at Aridis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
7/27/2021	Buy	5,000	$5.11	$25,550.00

Vu Truong Buying and Selling Activity at Aridis Pharmaceuticals

Aridis Pharmaceuticals Company Overview

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.

Today's Range

Now: $0.06

$0.06

$0.07

50 Day Range

MA: $0.07

$0.06

$0.08

2 Week Range

Now: $0.06

$0.05

$0.54

Volume

29,800 shs

Average Volume

102,253 shs

Market Capitalization

$3.02 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

Global crypto currency reset (41 major banks signed up)

From Stansberry Research | Ad

Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...

Here's everything you need to know.